NR1H4 and metabolic syndrome: Nevertheless, the strategy to introduce PPARγ activity has been excessively used in various approaches to multi-target drugs for MetS and were excellently reviewed by Ammazzalorso et al. (2019) Although not currently approved for humans, FXR agonists are being developed to treat metabolic diseases like NAFLD and fibrotic diseases (Ali et al., 2015; Oseini and Sanyal, 2017; Sumida and Yoneda, 2018).